SCHEMBL29637481

SCHEMBL29637481

O=C(Cl)c1cccc(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.65
ERCC5 P28715 1/20 0.53
FEN1 P39748 1/20 0.53
ALDH1A1 P00352 2/20 0.52
TSHR P16473 1/20 0.52
KCNK3 O14649 1/20 0.50
KCNK9 Q9NPC2 1/20 0.50
GRM5 P41594 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
KCNQ3 O43525 1/20 0.49
KCNQ2 O43526 1/20 0.49
KCNE1 P15382 1/20 0.49
KCNQ1 P51787 1/20 0.49
KCNMA1 Q12791 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL104419 1.00 PARP1 (0.65) PARP1ERCC5FEN1ALDH1A1TSHR
Trimethylammonium SCHEMBL28285756 0.92 ALDH1A1 (0.57) PARP1ERCC5FEN1ALDH1A1TSHR
SCHEMBL27510 0.85 ALDH1A1 (0.59) PARP1ALDH1A1TSHRL3MBTL1PKM
SCHEMBL3169530 0.83 PARP1 (0.68) PARP1ERCC5FEN1ALDH1A1KCNK3
SCHEMBL3173817 0.83 PARP1 (0.68) PARP1ERCC5FEN1ALDH1A1KCNK3
SCHEMBL2107465 0.82 KCNK3 (0.74) KCNK3KCNK9KCNQ3KCNQ2KCNE1
Hydrochloric Acid SCHEMBL8084573 0.82 ALDH1A1 (0.57) PARP1ALDH1A1TSHRL3MBTL1PKM
Bromide SCHEMBL31026552 0.82 ALDH1A1 (0.57) PARP1ALDH1A1TSHRL3MBTL1PKM
Iodide SCHEMBL29916276 0.82 ALDH1A1 (0.57) PARP1ALDH1A1TSHRL3MBTL1PKM
Benzene SCHEMBL9243917 0.82 ALDH1A1 (0.57) PARP1ALDH1A1TSHRHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4229005-B1 TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2024-12-25 EP claimed
US-20230356105-A1 TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) 2023-11-09 US claimed
EP-4229005-A1 TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR Ustav organicke chemie a biochemie AV CR, v.v.i. (CZ) 2023-08-23 EP claimed
WO-2022100769-A1 TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) 2022-05-19 WO claimed
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 EP disclosed
EP-3703692-B1 NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-07-23 EP disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 EP disclosed
EP-4229005-B1 TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2024-12-25 EP disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 WO disclosed
WO-2023239906-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-12-14 WO disclosed
US-20230356105-A1 TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) 2023-11-09 US disclosed
EP-4229005-A1 TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR Ustav organicke chemie a biochemie AV CR, v.v.i. (CZ) 2023-08-23 EP disclosed
EP-4065546-A1 ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE Gain Therapeutics SA (CH) 2022-10-05 EP disclosed
WO-2022100769-A1 TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) 2022-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230356105-A1 TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR SLC39A11, AOC1, PITHD1 PARP1 4077/4885ERCC5 2130/4885FEN1 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.